Follow us...

 

Search News Archives

Channels

News

 

 

View Channel

Laboratory Products

 

 

View Channel

Special Offers and Promotions

 

Microscopy | Image Analysis

 

 

View Channel

Separation Science

 

 

View Channel

Coronavirus (COVID-19)

 

 

View Channel

Research & Case Studies

 

 

View Channel

Conferences | Events

SPINNOVATION: CEO Frederic Girard joins fellow industry experts for a QbD round table

A new article detailing a round table discussion on quality by design (QbD) authored by leading industry experts including Spinnovation  Biologics CEO Frederic Girard is now available online.

Cell Culture Performance PredictionEntitled ‘QbD and PAT in Upstream and Downstream Processing’, the article details the fundamental principles of QbD, how it is used to improve process control, and the impact technological advances have made on QbD biopharmaceutical upstream process optimization. Originally published in the July addition of Biopharm International the full article is now available to read.

The implementation of QbD allows quality assurance to be built into each stage of the development and manufacturing process, ensuring the desired quality of the biological or biopharmaceutical product is guaranteed every time. In the new article Frederic Girard offers his perspectives on QbD, giving industry insight into modern biopharmaceutical process design. Mr Girard shows how critical quality attributes can be assessed in modern biopharmaceutical procedures, using the glycosylation of monoclonal antibodies as an illustration. The article goes on to cover the development of new analytical techniques and methodologies, such as NMR, to reduce performance variability and minimize process failure in large scale biopharmaceutical production.  

Spinnovation Biologics offers a variety of unique solutions to those looking to build QbD into biopharmaceutical manufacture. These include Spedia-PredictTM, a unique service utilizing a range of Spinnovation’s high-end analytics and chemometric techniques, including Spedia-NMRTM, NMR fingerprinting, LC-MS profiling and ICP-OES elemental analysis, to assess critical quality attributes and troubleshoot bio-manufacturing performance issues. Methods such as Spedia-NMRTM allow operators to analyze fermentation media to monitor the uptake of metabolites and nutrients by the cells, providing full visibility of the presence and concentration of feed components, contaminants and metabolites. Spinnovation’s range of analysis services is also available individually, on a contract or pay-per-sample basis.

“Quality by design is becoming an essential aspect of drug manufacture, particularly within biopharmaceuticals”, commented Mr Girard. “However the variability and complexities associated with the upstream biological production makes incorporating QbD a complicated process. Spinnovation Technology provides a unique and specialized service, assessing the critical quality attributes of specific biopharmaceutical manufacturing procedures and finding new and better ways for manufacturers to optimize their process.”


more about published article


more about Spinnovation


more news from Spinnovation


 



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

Today's Picks

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners